OncoSec Medical (NSDQ:ONCS) said today that it won Fast Track Designation from the FDA for its ImmunoPulse IL-12 electroporation gene therapy for the treatment of metastatic melanoma.
The biotech company’s electroporation device is designed to locally deliver DNA-based interleukin-12 to stimulate the immune system and fight off cancer cells. The ImmunoPulse device delivers a sequence of short-duration electrical pulses to increase the cancer cell membrane’s permeability and more efficiently deliver the IL-2 gene therapy.
Get the full story at our sister site, Drug Delivery Business News.
The post OncoSec wins fast track designation for electroporation combo therapy appeared first on MassDevice.
from MassDevice http://ift.tt/2lgr50q
Cap comentari:
Publica un comentari a l'entrada